- Home
- CSTL vs GBLI Comparison
CSTL vs GBLI Comparison
Compare CSTL & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- GBLI
- Stock Information
- Founded
- CSTL 2007
- GBLI 2016
- Country
- CSTL United States
- GBLI United States
- Employees
- CSTL N/A
- GBLI N/A
- Industry
- CSTL Medical Specialities
- GBLI Property-Casualty Insurers
- Sector
- CSTL Health Care
- GBLI Finance
- Exchange
- CSTL Nasdaq
- GBLI Nasdaq
- Market Cap
- CSTL 576.3M
- GBLI 476.1M
- IPO Year
- CSTL 2019
- GBLI 2003
- Fundamental
- Price
- CSTL $19.78
- GBLI $34.95
- Analyst Decision
- CSTL Strong Buy
- GBLI
- Analyst Count
- CSTL 6
- GBLI 0
- Target Price
- CSTL $40.00
- GBLI N/A
- AVG Volume (30 Days)
- CSTL 403.1K
- GBLI 5.6K
- Earning Date
- CSTL 05-01-2025
- GBLI 05-07-2025
- Dividend Yield
- CSTL N/A
- GBLI 4.01%
- EPS Growth
- CSTL N/A
- GBLI 70.49
- EPS
- CSTL 0.62
- GBLI 3.12
- Revenue
- CSTL $332,069,000.00
- GBLI $441,087,000.00
- Revenue This Year
- CSTL N/A
- GBLI $8.70
- Revenue Next Year
- CSTL $6.01
- GBLI $14.56
- P/E Ratio
- CSTL $32.29
- GBLI $11.04
- Revenue Growth
- CSTL 51.09
- GBLI N/A
- 52 Week Low
- CSTL $16.97
- GBLI $29.65
- 52 Week High
- CSTL $35.84
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- CSTL 36.62
- GBLI 45.98
- Support Level
- CSTL $19.22
- GBLI $34.20
- Resistance Level
- CSTL $20.30
- GBLI $36.61
- Average True Range (ATR)
- CSTL 0.81
- GBLI 0.68
- MACD
- CSTL 0.23
- GBLI -0.17
- Stochastic Oscillator
- CSTL 43.33
- GBLI 26.81
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among others. The company's test portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology, and ophthalmology and a pharmacogenomics ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety, and other mental health conditions.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.